Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 3
1966 1
1967 1
1975 1
1983 2
1984 4
1994 2
1998 1
2000 2
2001 1
2002 1
2003 1
2004 3
2005 4
2006 7
2007 6
2008 5
2009 3
2010 6
2011 6
2012 5
2013 5
2014 4
2015 7
2016 7
2017 6
2018 5
2019 8
2020 18
2021 17
2022 16
2023 12
2024 17
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
Unexpected Rearrangement Reactions of the 14-Aminonaltrexone Skeleton.
Maeda K, Ohrui S, Tokuda A, Nagumo Y, Yamamoto N, Tanimura R, Saitoh T, Kutsumura N, Nagase H. Maeda K, et al. Among authors: nagumo y. Org Lett. 2023 May 19;25(19):3407-3411. doi: 10.1021/acs.orglett.3c00956. Epub 2023 May 8. Org Lett. 2023. PMID: 37154730
Bmal1 Regulates Prostate Growth via Cell-Cycle Modulation.
Ueda M, Kono J, Sengiku A, Nagumo Y, Mathis BJ, Shimba S, Taketo MM, Kobayashi T, Ogawa O, Negoro H. Ueda M, et al. Among authors: nagumo y. Int J Mol Sci. 2022 Sep 24;23(19):11272. doi: 10.3390/ijms231911272. Int J Mol Sci. 2022. PMID: 36232573 Free PMC article.
Design and Synthesis of Orexin 1 Receptor-Selective Agonists.
Iio K, Hashimoto K, Nagumo Y, Amezawa M, Hasegawa T, Yamamoto N, Kutsumura N, Takeuchi K, Ishikawa Y, Yamamoto H, Tokuda A, Sato T, Uchida Y, Inoue A, Tanimura R, Yanagisawa M, Nagase H, Saitoh T. Iio K, et al. Among authors: nagumo y. J Med Chem. 2023 Apr 27;66(8):5453-5464. doi: 10.1021/acs.jmedchem.2c01773. Epub 2023 Apr 12. J Med Chem. 2023. PMID: 37043436
TNFSF9 Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and Ipilimumab.
Isoda B, Kandori S, Sazuka T, Kojima T, Nitta S, Shiga M, Nagumo Y, Fujimoto A, Arai T, Sato H, Mathis BJ, Wu CL, Jan YH, Ichikawa T, Nishiyama H. Isoda B, et al. Among authors: nagumo y. Int J Mol Sci. 2024 Jul 6;25(13):7444. doi: 10.3390/ijms25137444. Int J Mol Sci. 2024. PMID: 39000552 Free PMC article.
Favorskii-Type Rearrangement of the 4,5-Epoxymorphinan Skeleton.
Kutsumura N, Koyama Y, Suzuki Y, Tominaga KI, Yamamoto N, Saitoh T, Nagumo Y, Nagase H. Kutsumura N, et al. Among authors: nagumo y. Org Lett. 2018 Mar 16;20(6):1559-1562. doi: 10.1021/acs.orglett.8b00288. Epub 2018 Mar 7. Org Lett. 2018. PMID: 29513016
Efficacy and Safety of Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Interim Analysis from a Multicenter, Open-label, Prospective Phase 2 Trial.
Kimura T, Ishikawa H, Nagumo Y, Sekino Y, Kageyama Y, Ushijima H, Kawai T, Yamashita H, Azuma H, Nihei K, Takemura M, Hashimoto K, Maruo K, Tsuzuki T, Nishiyama H; BPT-ART Investigators Group. Kimura T, et al. Among authors: nagumo y. Int J Radiat Oncol Biol Phys. 2023 Nov 1;117(3):644-651. doi: 10.1016/j.ijrobp.2023.05.013. Epub 2023 May 15. Int J Radiat Oncol Biol Phys. 2023. PMID: 37196834 Free article. Clinical Trial.
183 results